Journal of Molecular Neuroscience

, Volume 43, Issue 3, pp 290–302

Membrane Lipid Modification by Docosahexaenoic Acid (DHA) Promotes the Formation of α-Synuclein Inclusion Bodies Immunopositive for SUMO-1 in Oligodendroglial Cells After Oxidative Stress

  • Michael Riedel
  • Olaf Goldbaum
  • Michael Wille
  • Christiane Richter-Landsberg


α-Synuclein (α-syn) is the major constituent of Lewy bodies and glial cytoplasmic inclusions which are pathological hallmarks of neurodegenerative disorders like Parkinson’s disease or multiple system atrophy (MSA), respectively. It accumulates and aggregates during the pathogenic process, and missense mutations, such as A53T, are increasing its probability of aggregate formation. Furthermore, α-syn interacts with polyunsaturated fatty acids, and this interaction may promote the oligomerization process. To investigate whether membrane lipid modification by docosahexaenoic acid (DHA) modifies the aggregation process of α-syn in oligodendroglial cells, we have used OLN-93 cells stably expressing the human α-syn A53T mutation. Cells were supplemented with DHA (25 μM) for 3 days and then subjected to oxidative stress (OS) exerted by hydrogen peroxide. The data show that modification of the oligodendroglial cell membranes by DHA followed by OS caused the formation of fibrillary α-syn inclusions, a decrease in α-syn solubility, and an increase in phosphorylation at serine 129, which has been suggested to play a proaggregatory role. The aggregates contain αB-crystallin and ubiquitinated proteins and SUMO-1 immunoreactivity. SUMO-1 has been implicated in protein aggregation and identified as a constituent in inclusion bodies in MSA. Hence, membrane lipid modification in oligodendroglial cells promotes the formation of α-syn inclusion bodies resembling protein aggregates in neurodegenerative disease. This effect is not only attributable to the A53T mutation but also is observable in OLN cells expressing wild-type α-syn.


Oligodendrocytes Glial inclusion bodies Polyunsaturated fatty acid α-Synuclein SUMO 


  1. Alessandri JM, Guesnet P, Vancassel S et al (2004) Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 44:509–538CrossRefPubMedGoogle Scholar
  2. Bossis G, Melchior F (2006) Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol Cell 21:349–357CrossRefPubMedGoogle Scholar
  3. Brand A, Yavin E (2001) Early ethanolamine phospholipid translocation marks stress-induced apoptotic cell death in oligodendroglial cells. J Neurochem 78:1208–1218CrossRefPubMedGoogle Scholar
  4. Brand A, Gil S, Yavin E (2000) N-Methyl bases of ethanolamine prevent apoptotic cell death induced by oxidative stress in cells of oligodendroglia origin. J Neurochem 74:1596–1604CrossRefPubMedGoogle Scholar
  5. Brand A, Gil S, Seger R, Yavin E (2001) Lipid constituents in oligodendroglial cells alter susceptibility to H2O2-induced apoptotic cell death via ERK activation. J Neurochem 76:910–918CrossRefPubMedGoogle Scholar
  6. Brand A, Bauer NG, Hallot A, Goldbaum O, Ghebremeskel K, Reifen R, Richter-Landsberg C (2010) Membrane lipid modification by polyunsaturated fatty acids sensitizes oligodendroglial OLN-93 cells against oxidative stress and promotes upregulation of heme oxygenase-1 (HSP32). J Neurochem 113:465–476CrossRefPubMedGoogle Scholar
  7. Burn DJ, Jaros E (2001) Multiple system atrophy: cellular and molecular pathology. Mol Pathol 54:419–426PubMedGoogle Scholar
  8. Castagnet PI, Golovko MY, Barcelo-Coblijn GC, Nussbaum RL, Murphy EJ (2005) Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J Neurochem 94:839–849CrossRefPubMedGoogle Scholar
  9. Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson’s disease. Nat Neurosci 8:657–663CrossRefPubMedGoogle Scholar
  10. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443–9449CrossRefPubMedGoogle Scholar
  11. De Franceschi G, Frare E, Bubacco L, Mammi S, Fontana A, de Laureto PP (2009) Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid. J Mol Biol 394:94–107CrossRefPubMedGoogle Scholar
  12. Dennery PA (2000) Regulation and role of heme oxygenase in oxidative injury. Curr Top Cell Regul 36:181–199CrossRefPubMedGoogle Scholar
  13. Dorval V, Fraser PE (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281:9919–9924CrossRefPubMedGoogle Scholar
  14. Dorval V, Fraser PE (2007) SUMO on the road to neurodegeneration. Biochim Biophys Acta 1773:694–706CrossRefPubMedGoogle Scholar
  15. Dyall SC, Michael-Titus AT (2008) Neurological benefits of omega-3 fatty acids. Neuromolecular Med 10:219–235CrossRefPubMedGoogle Scholar
  16. Forman MS, Trojanowski JQ, Lee VM (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10:1055–1063CrossRefPubMedGoogle Scholar
  17. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164CrossRefPubMedGoogle Scholar
  18. Geiss-Friedlander R, Melchior F (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8:947–956CrossRefPubMedGoogle Scholar
  19. Giannakis E, Pacifico J, Smith DP, Hung LW, Masters CL, Cappai R, Wade JD, Barnham KJ (2008) Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim Biophys Acta 1778:1112–1119CrossRefPubMedGoogle Scholar
  20. Goldbaum O, Oppermann M, Handschuh M, Dabir D, Zhang B, Forman MS, Trojanowski JQ, Lee VM, Richter-Landsberg C (2003) Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid. J Neurosci 23:8872–8880PubMedGoogle Scholar
  21. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634–1658CrossRefPubMedGoogle Scholar
  22. Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm 116:1111–1162CrossRefPubMedGoogle Scholar
  23. Kahle PJ, Neumann M, Ozmen L et al (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3:583–588CrossRefPubMedGoogle Scholar
  24. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH (2009) {alpha}-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211–10222CrossRefPubMedGoogle Scholar
  25. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774–779CrossRefPubMedGoogle Scholar
  26. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr (2002) alpha-Synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089–1102CrossRefPubMedGoogle Scholar
  27. Lee HJ, Lee SJ (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277:48976–48983CrossRefPubMedGoogle Scholar
  28. Lee VM, Giasson BI, Trojanowski JQ (2004) More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 27:129–134CrossRefPubMedGoogle Scholar
  29. Martin S, Wilkinson KA, Nishimune A, Henley JM (2007) Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci 8:948–959CrossRefPubMedGoogle Scholar
  30. Neuhoff V, Philipp K, Zimmer HG, Mesecke S (1979) A simple, versatile, sensitive and volume-independent method for quantitative protein determination which is independent of other external influences. Hoppe Seylers Z Physiol Chem 360:1657–1670PubMedGoogle Scholar
  31. Norris EH, Giasson BI, Ischiropoulos H, Lee VM (2003) Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278:27230–27240CrossRefPubMedGoogle Scholar
  32. Perrin RJ, Woods WS, Clayton DF, George JM (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 276:41958–41962CrossRefPubMedGoogle Scholar
  33. Pountney DL, Chegini F, Shen X, Blumbergs PC, Gai WP (2005) SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. Neurosci Lett 381:74–79CrossRefPubMedGoogle Scholar
  34. Richter-Landsberg C, Heinrich M (1996) OLN-93: a new permanent oligodendroglia cell line derived from primary rat brain glial cultures. J Neurosci Res 45:161–173CrossRefPubMedGoogle Scholar
  35. Richter-Landsberg C, Bauer NG (2004) Tau-inclusion body formation in oligodendroglia: the role of stress proteins and proteasome inhibition. Int J Dev Neurosci 22:443–451CrossRefPubMedGoogle Scholar
  36. Riedel M, Goldbaum O, Richter-Landsberg C (2009) alpha-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J Mol Neurosci 39:226–234CrossRefPubMedGoogle Scholar
  37. Ross CA, Poirier MA (2005) Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 6:891–898CrossRefPubMedGoogle Scholar
  38. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ (2001) alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci USA 98:9110–9115CrossRefPubMedGoogle Scholar
  39. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37:583–595CrossRefPubMedGoogle Scholar
  40. Stahnke T, Stadelmann C, Netzler A, Bruck W, Richter-Landsberg C (2007) Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci 32:25–37CrossRefPubMedGoogle Scholar
  41. Stöckl M, Fischer P, Wanker E, Herrmann A (2008) alpha-Synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains. J Mol Biol 375:1394–1404CrossRefPubMedGoogle Scholar
  42. Um JW, Chung KC (2006) Functional modulation of parkin through physical interaction with SUMO-1. J Neurosci Res 84:1543–1554CrossRefPubMedGoogle Scholar
  43. Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18:357–362CrossRefPubMedGoogle Scholar
  44. Yavin E (2006) Docosahexaenoic acid: a pluripotent molecule acting as a membrane fluidizer, a cellular antioxidant and a modulator of gene expression. Nutr Health 18:261–262PubMedGoogle Scholar
  45. Yavin E, Brand A, Green P (2002) Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr Neurosci 5:149–157CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Michael Riedel
    • 1
  • Olaf Goldbaum
    • 1
  • Michael Wille
    • 1
  • Christiane Richter-Landsberg
    • 1
  1. 1.Department of Biology, Molecular NeurobiologyUniversity of OldenburgOldenburgGermany

Personalised recommendations